Harmony Biosciences reported third-quarter 2026 WAKIX net revenue of $268.9 million, up 12% from $239.5 million a year earlier, and reiterated full-year WAKIX net revenue guidance of $1.0 billion to $1.04 billion. Net income fell to $48.2 million, or $0.81 per diluted share, from $50.9 million, or $0.87, a year earlier, mainly due to higher milestone charges and new royalty charges tied to the Novitium license.
Q3 2026 WAKIX net revenue of $268.9 million, up 12% from $239.5 million in Q3 2025
Net income of $48.2 million, or $0.81 per diluted share, versus $50.9 million, or $0.87, in Q3 2025
Full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion reiterated
Peter Anastasiou will succeed Jeffrey Dayno, MD, as President and CEO effective January 1, 2027
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Harmony Biosciences Holdings, Inc.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$868.45M
+21.5%
$2.71
+8.0%
18.3%
FY2024
$714.73M
+22.8%
$2.51
+17.8%
20.4%
FY2023
$582.02M
+32.9%
$2.13
-28.3%
22.1%
FY2022
$437.86M
+43.4%
$2.97
+412.1%
41.4%
FY2021
$305.44M
+91.2%
$0.58
—
11.3%
Frequently asked questions
When is Harmony Biosciences Holdings's next earnings date?
Harmony Biosciences Holdings has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Harmony Biosciences Holdings earn last quarter?
For the quarter ended Sep 2026, Harmony Biosciences Holdings reported diluted EPS of $0.81 (-6.9% year over year) on revenue of $268.92M (+12.3%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.